Furthermore, long-term studies are needed to assess the sustained impact of targeting the ZFAS1/STAT3 axis on CML progression, relapse rates, and overall patient survival. This evidence concerns the gene ZFAS1 and chronic myelogenous leukemia, BCR-ABL1 positive.